FIELD: biotechnology.
SUBSTANCE: disclosed are antigen-binding receptors containing an anchored transmembrane domain and an extracellular domain comprising an antigen-binding fragment. Antigen-binding receptors specifically bind to mutated Fc-domains, but do not bind to unmutated initial Fc-domains.
EFFECT: invention provides specific activation of transduced T-cells expressing said antigen-binding receptors in the presence of an IgG antibody with a mutated Fc-domain for effective lysis of tumour target cells.
31 cl, 35 dwg, 12 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| BISPECIFIC ANTIBODIES SPECIFIC RELATIVELY TO COSTIMULATORY TNF-RECEPTOR | 2016 |
|
RU2761115C1 |
| ANTIBODIES BINDING TO CD3 | 2019 |
|
RU2810924C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| ANTI-SIRPα ANTIBODIES | 2018 |
|
RU2771174C2 |
